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Available online 22 August 2012Abstract An established rat intracranial glioma was successfully treated through the tumoricidal bystander effect generated
by intratumoral injection of rat bone marrow stromal cells (BMSCs) transduced with the herpes simplex virus-thymidine kinase
gene (BMSCtk cells) followed by systemic ganciclovir administration. In the present study, we tested the bystander effect of
this treatment strategy when using human BMSCs as the vector cells. Human BMSCtk cells were mixed with various kinds of
brain tumor cell lines (human and rat glioma cells) and examined in vitro and in vivo tumoricidal bystander effects, by co-
culture study and co-implantation study in the nude mouse, respectively. A significant in vitro bystander effect was observed
between human BMSCtk cells and any of the tumor cells examined in the ganciclovir-containing medium. A potent in vivo
bystander effect against human and rat glioma cells was also demonstrated when ganciclovir was administered. Migratory
activity of the human BMSCs toward the tumor cells was enhanced by the conditioned media obtained from both human and rat
glioma cells compared to the fresh media. The results of this study have demonstrated that the bystander effect generated by
BMSCtk cells and ganciclovir is not cell type-specific, suggesting that the strategy would be quite feasible for clinical use.
© 2012 Elsevier B.V. All rights reserved.Introduction diagnosis and this has not significantly improved for moreGlioblastomas, the most common and malignant primary brain
tumor, have a dismal prognosis, despite modern refinement of
diagnostic techniques and treatment strategy including surgery
and radio/chemotherapy. Median survival of the patients with
glioblastoma is generally about a year from the time of⁎ Corresponding author. Fax: +81 53 435 2282.
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http://dx.doi.org/10.1016/j.scr.2012.08.002than three decades (DeAngelis, 2001; Stewart, 2002; Stupp et
al., 2005). As a novel treatment strategy, gene therapies using
the herpes simplex virus-thymidine kinase (HSVtk) gene and
ganciclovir (GCV) were clinically tested (Rainov, 2000; Ram et
al., 1997). However, the results were unsatisfactory partly due
to limited migratory activity of the vector-producing cells
derived from fibroblasts, which could not cover all of the
glioma cells that widely infiltrated into the surrounding brain
tissues. To improve the migratory activity of the effector cells,
use of the neural stem cells and bone marrow stromal cells
(BMSCs), that display extensive tropism for brain lesions
including gliomas, has been introduced (Aboody et al., 2000;
271Bystander effect using bone marrow stromal cellsBenedetti et al., 2000; Li et al., 2007). In the previous study,
we demonstrated that established intracranial glioma in the rat
brain was successfully treated by intratumoral injection of
BMSCs transduced with HSVtk gene (BMSCtk cells) followed by
intraperitoneal GCV administration (Amano et al., 2009). This
is mainly due to a very potent “bystander effect”, where tumor
cells that are not transduced with HSVtk gene are eliminated
when mixed with HSVtk-expressing cells by GCV administration
(Culver et al., 1992), as well as an active tumor tracking ability
of BMSCs (Lee et al., 2003; Nakamizo et al., 2005). In fact, we
have demonstrated a surprisingly potent bystander effect
between BMSCtk and C6 rat glioma cells (Amano et al., 2009).
These observations suggest that “BMSCtk therapy” is promising
as a novel clinical treatment strategy for glioblastomas.
Bystander effect between HSVtk-positive cells and HSVtk-
negative cells has been extensively studied especially from the
aspect of cell-to-cell communication. Connexin43, a major
molecule in the connexin family gene products, has been
reported to be related to the bystander effect in suicide gene
therapies (Dilber et al., 1997; Elshami et al., 1886; Mesnil et
al., 1996; Vrionis et al., 1997; Ziu et al., 2006). We previously
tested bystander effect between HSVtk-positive and HSVtk-
negative tumor cells and found that the bystander effect was
very potent in 9L cells with high connexin43 expression
compared with in C6 cells with low connexin43 expression
(Namba et al., 2001). However, we consequently found that
the bystander effects between BMSCtk and C6 cells were very
potent. In the present study, we examined bystander effect
generated by human and rat BMSCtk cells on various kinds of
human and rat brain tumor cells in both in vitro and in vivo
conditions. The results have demonstrated that tumoricidal
bystander effect in the suicide gene therapy using BMSCtk cells
and GCV is not cell type- and species-specific, suggesting a
possibility of “BMSCtk therapy” using pre-established BMSCtk
cell.Materials and methods
Establishment of human BMSCtk cells
The human BMSCs (from female of 19 years of age) and human
BMSC growth medium were purchased from Cambrex Bio
Science Walkersville, Inc. (Walkersville, MD). Thawing of cells
and initiation of culture process were performed based on the
manufacturer's instruction. Human BMSCs were plated in 10 cm
tissue culture dishes in the concentration of 5×103 cells/cm2
and cultured with human BMSC growth medium. Medium was
changed every 2–3 days. The HSVtk retrovirus-producing cells
(PA317;mouse fibroblast cell line withHSVtk gene) were kindly
provided by Genetic Therapy Inc. (Gaithersburg, MD). The
PA317 cells were cultured in the medium for 48 h and the
supernatant was collected, filtered through 0.22 μm filter
(Toyo Roshi Kaisha, Ltd) and the retrovirus containing superna-
tant was stored in −80 °C until following use. The method of
infecting the BMSCs was described previously (Namba et al.,
2000). Briefly, the BMSCswere plated at 5×103 cells/cm2 in the
human BMSC growth medium in a 25-cm2 tissue culture flask
and cultured for 24 h. Thereafter, the medium was replaced
with 3 ml fresh medium and 1 ml of the supernatant of HSVtk
retrovirus in the presence of 8 μg/ml Polybrene (Aldrich
Chemical Company Inc., Milwaukee, WI) for 5 h. After washing,the cells were maintained with fresh medium. The drug
selection with 150 μg/ml G418 (Sigma-Aldrich Japan K.K.,
Tokyo, Japan) was performed for 1 week. The drug-resistant
cells were collected and used for further experiments (BMSCtk
cells).
Establishment of rat BMSCtk cells
All the following experiments were performed according to
the Rules of Animal Experimentation and the Guide for the
Care and Use of Laboratory animals of the Hamamatsu
University School of Medicine. BMSCs were obtained from
6-week Sprague–Dawley rats as previously described (Gu et
al., 2010). Briefly, bone marrow from the femora and tibia
bone was suspended in murine BMSC culture medium (Stem
Cell Technologies Inc. Mesencult®) after aspiration by 5 ml
syringe connected with 23 G needle. Depletion of macrophages
was not performed. The total bone marrow cells were filtered
through a 70 μm nylon cell strainer and plated in 10 cm tissue
culture dished in the concentration of 5×103 cells/cm2. New
medium was changed 24 h later and then every 2–3 days.
BMSCs attach on the bottom of the dishes and form colonies.
The HSVtk gene transfer methods and drug selection were the
same as described above except using murine BMSC medium
instead of human BMSC growth medium.
In vitro sensitivity of human BMSCtk cells to GCV
To test the sensitivity to GCV, the obtained human BMSCtk
cells and wild-type BMSCs were cultured in the medium
containing various concentrations (0.01 to 1000 μg/ml) of
GCV (Syntex Chemical Inc., Palo Alto, CA) in a 96-well plate
(1×104 cells/well) and were incubated for 7 days. Viability
of the cells was estimated using the tetrozolium-based
colorimetric assay (MTT assay) (Mosmann, 1983).
In vitro bystander effect between BMSCtk and
various glioma cell lines
Human glioblastoma (A-172, YKG-1, T98G), medulloblasto-
ma (Daoy, TE671) cell lines and rat glioma cell lines (C6, 9L)
were obtained from the American Type Culture Collection
(Manassas, VA) and the Human Science Research Bank
(Osaka, Japan).
Tumor cells (5×103) were co-cultured with the same
number of human or rat BMSCtk in complete DMEM medium
with/without containing 1 μg/mlGCV in a 96-well tissue culture
plate. As another controls, 5×103 tumor cells were cultured
alone in the medium with/without GCV. The conditional
medium was changed every 2 days and the number of living
cells was determined by MTT assay on day 7. Viability of the
cells was expressed as the percent absorbance of the respective
tumor cells alone cultured without GCV.
In vivo bystander effect between human BMSCtk and
glioma cells in nude mice
We anesthetized 60 female BALB/c nude mice (19–21 g,
9 weeks old, Nippon SLC, Hamamatsu, Japan) with
0.4 ml/100 g Equithesin and placed in a stereotaxic apparatus
Figure 1 In vitro bystander effect between human BMSCtk and various tumor cells (human and rat glioma, human
medulloblastoma cell lines) tested with MTT assay (A). The proliferation of glioma cells co-cultured with BMSCtk cells was
significantly inhibited when they were cultured in the presence of GCV (1 μg/ml, gray column, triplicate, mean±standard error)
compared to when cultured without GCV (open column, pb0.01). In vitro bystander effect with rat BMSCtk cells showed similar
results as human BMSCtk cells (B).
Figure 2 The tumor volume for each group (n=5,mean±standard error) on day 21 (A).When treatedwith GCV for 10 days, no tumorwas
observed in the mice co-implanted with human BMSCtk and human glioma cells (A-172 and T98G) and only small tumors were observed in
the mice co-implanted with human BMSCtk and rat C6 glioma cells (arrow). When treated with PBS, a large tumor (5–6 mm3) developed in
the mice co-implanted with BMSCtk and glioma cells, which was not significantly different from the sizes of tumors in the mice
implanted with tumor cells only regardless of GCV administration. Representative photomicrographs of coronal brain sections are
shown (B, bar: 1 mm).
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Figure 3 Kaplan–Meier survival curves of the mice for each
tumor cell line. The mice co-implanted with a mixture of human
BMSCtk and human glioma cells (A-172 and T98G) and treatedwith
GCV for 10 days survived more than 100 days (red lines), while
those co-implanted with a mixture but treated with PBS (black
lines) and those implanted with tumor cells only and treated with
GCV (pink lines) or PBS (green lines) died in 3 weeks (there were
no difference among those three groups). The mice co-implanted
with a mixture of human BMSCtk and rat C6 glioma cells and
treated with GCV for 10 days survived significantly longer than the
other three groups and 2 out of 5 mice survived more than
100 days (red line).
273Bystander effect using bone marrow stromal cells(Narishige Scientific Instrument Lab., Tokyo, Japan). The
method of cell implantation was the same as previously
described (Li et al., 2007). Briefly, 2×104 tumor cells (A-172,
T98G, or C6 cells) with/without 2×104 human BMSCtk were
infused with a 10 μl microsyringe (Hamilton Company, Reno,
NV) to the point of 3 mmventral from the dura through the burr
hole (co-ordinates with respect to bregma: 0.2 mm posterior,
2 mm right) for 5 min. Half of the animals (n=5) for each group
underwent intraperitoneal administration of 50 mg/kg of GCV
twice daily (100 mg/kg/day) from day 0 for 10 days, and the
other half (n=5), phosphate-buffered saline (PBS). All the
animals were killed on day 21 for histological analyses. Serial
coronal sections (5 μm) were obtained and stained with
hematoxylin and eosin. The tumor area of each section was
measured using NIH Image software (rsbweb.nih.gov). The
total volume of the tumor (mm3)was calculated by summing up
the cross-sectional areas.
Another 60 mice were treated in the sameway as above for
the survival study. When the mice developed symptoms such
as severe paresis and/or ataxia, or when their body weight
decreased to less than 80%, they were euthanized. Survivalwas analyzed by a log-rank test based on the Kaplan–Meier
test using Statview 5.0 software.
Another 10 mice were implanted with 2×104 human BMSCtk
alone to test tumorigenicity of BMSCtk cells. When the animals
survived more than 100 days, they were euthanized and the
brains were taken for histological analyses.In vitro migration assay
The in vitromigratory capacity of human BMSCtk cells, another
important factor for the success of “BMSCtk therapy”, was then
assessed using the 24-well Matrigel Invasion Chamber (BD
Biosciences Discovery Labware, Bedford, MA), which contains
an 8-μm pore size PET membrane that has been treated with
Matrigel Basement Membrane Matrix in the insert (Li et al.,
2007; Mohanam et al., 1993). First, 0.5 ml Dulbecco's Modified
Eagle's Medium (DMEM) (without serum) was added to the
interior of the inserts and bottom of wells and allowed to
rehydrate for 2 h at 37 °C under 5% CO2. Then, themediumwas
carefully removed without disturbing the layer of Matrigel
Matrix on the membrane. The BMSCtk cells were washed twice
in BMSC growth medium and resuspended to 1×105 cells/ml.
0.5 ml of the cell suspension (5×104 cells) was added to the
upper insert. The lower chamber was filled with 0.75 ml
conditioned medium obtained by incubating C6 cells for 24 h
in DMEM (with or without 10% fetal bovine serum (FBS)) or
unconditioned fresh DMEM (with or without 10% FBS). After
incubating the Matrigel Invasion Chambers for 24 h at 37 °C
under 5% CO2, the non-invading cells and/or Matrigel Matrix
were removed from the upper surface of the membrane in
the inserts with a cotton swab. The cells migrating to the
lower surface of the membrane were stained with the Diff-
Quik kit (International Reagents), which was accomplished
by sequentially transferring the inserts through three
solutions and allowing the inserts to air dry. Ten random
fields per membrane were counted using ×200 magnifica-
tion. Each assay was performed in triplicate, and results
were expressed as the mean number of cells migrating per
field±standard error. At the same time, 0.5 ml of the cell
suspension (5×104 cells) of PA317 or C6 cells in DMEM
(containing 0.1% BSA) was also tested for their migratory
capacity using the same conditioned medium as described
above.Results
In vitro sensitivity of human BMSCtk cells to GCV
Human BMSCtk cells were cultured in the medium containing
various concentrations (0.01 to 1000 μg/ml) of GCV and the
viability of the cells was tested with MTT assay (Mosmann,
1983). At a GCV concentration of 1 μg/ml, almost no BMSCtk
cells survived, while no significant toxicity was observed on
wild-type BMSCs. The 100% lethal dose of GCV for wild-type
BMSCs was 300 μg/ml, 100 times higher than that of BMSCtk
cells (Supplementary Fig. 1). We used a 1 μg/ml GCV in the
following in vitro studies, because this concentration of GCV
killed all BMSCtk cells but not wild-type BMSCs and tumor
cells.
Figure 4 In vitro migratory capacity of human BMSCtk cells when they were exposed to different media. 0.5 ml of the BMSCtk cell
suspension was added to the upper insert of Matrigel Invasion Chamber and the lower chamber was filled with 0.75 ml of the
conditioned DMEM obtained by incubating human glioma cells (A-172, T98G) or rat C6 cells for 24 h or fresh DMEM (with or without 10%
FBS). BMSCtk cells showed a potent migratory capacity when the conditioned medium was used as attractant in the lower chamber,
while only a few migrating BMSCtk cells could be observed when they were exposed to the fresh DMEM. The migration was further
enhanced with 10% FBS. A: Mean number of migrating cells±standard error (triplicate). B: Representative photomicrographs of the
micropore membrane after cell migration.
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tumor cell lines
The proliferation of tumor cells, irrespective of human or
rat cells, co-cultured with human BMSCtk cells in the
presence of GCV (1 μg/ml) (Fig. 1A, closed column) was
significantly inhibited as compared to that without GCV
(Fig. 1A, open column), which was not different from the
proliferation of tumor cells cultured alone with or without
GCV (data not shown). This is due to a significant bystander
effect between human BMSCtk and tumor cells. Relative
viability of “tumor+BMSCtk” groups was around 100% (Fig. 1A,
open column), suggesting that BMSCtk did not have significant
stimulatory or inhibitory effects on tumor cell proliferation.
When BMSCs (and not BMSCtk cells) were co-cultured with
tumor cells in the GCV containing medium, no bystander
effect was exerted (data not shown). The similar bystander
effect was also observed between rat BMSCtk and various tumor
cells (Fig. 1B). These observations suggested that the in vitro
bystander effect generated by BMSCtk cells and GCV was not
specific to tumor cell types and species.
In vivo bystander effect between human BMSCtk and
glioma cell lines
Since a potent in vitro bystander effect was observed between
human BMSCtk and various tumor cells, we then tested in vivo
bystander effect by an intracranial co-implantation study of
human BMSCtk and glioma cells in the nude mouse. Whentumor cells alone were implanted, a large tumor (5-6 mm3)
developed regardless of GCV administration (Fig. 2A). When
a mixture of BMSCtk and human glioma cells (A-172 and
T98G) was co-implanted, no tumor was observed in the GCV
group, while tumors of similar sizes as those of the tumor-
alone groups developed in the PBS group (Fig. 2A). Repre-
sentative mouse brain sections of each group were shown
in Fig. 2B (A-172, T98G). The survival times of the mice
implanted with a mixtures of BMSCtk and human glioma
cells and treated with GCV (Fig. 3, A-172 and T98G, red
lines) were more than 100 days, while those treated with
PBS were about 3 weeks (black lines), which were similar to
those of the tumor-alone groups treated with GCV (pink
lines) or PBS (green lines). All the mice implanted with
BMSCtk alone survived more than 100 days and no tumor
formation was observed (Fig. 2A).
Surprisingly, a similar in vivo bystander effect was observed
between BMSCtk and rat C6 glioma cells (Fig. 2, C6). When
human BMSCtk cells were mixed with rat C6 cells and co-
implanted into themice brain, small tumors developed in some
mice of the GCV group (Fig. 2B, arrow). The survival was also
significantly prolonged in the GCV group and 2 out of 5 mice
survived more than 100 days (Fig. 3, C6).
In vitro migration of human BMSCtk cells to the
conditioned medium
Migratory activity of human BMSCtk cells was evaluated in
Matrigel invasion assay (Li et al., 2007; Mohanam et al.,
275Bystander effect using bone marrow stromal cells1993). BMSCtk cells actively migrated through the Matrigel
Matrix layer and micropore when the lower chamber was
filled with the conditioned medium from the tumor cells,
while they hardly migrated when the lower chamber was
filled with the fresh DMEM (pb0.01, Fig. 4). The migratory
capacity of BMSCtk cells to the tumor conditioned medium
was further enhanced when 10% FBS was added in the lower
chamber compared with respective controls (pb0.01,
Fig. 4).Discussion
We used commercially-available human BMSCs as the vector
cells in the present study. Thus, a limitation of the present
study is that the commercially-available BMSCs do not
represent general BMSCs that are obtained from the patients.
They may not behave as “stem cells” that have multipotent
differentiation capacity, and therefore, more studies are
obviously needed to establish ideal vector cells for clinical
use. Induced pluripotent stem cells, recently established and
vigorously examined in the field of reconstructive neurosci-
ences, could be also suitable vehicles for gene therapy
(Takahashi et al., 2007; Yu et al., 2007). We have recently
confirmed that induced pluripotent stem cells have a potent
migratory activity toward the conditioned medium of brain
tumors and this activity is also not tumor cell type-specific, or
dependent on the species as shown in the present migration
assay (Koizumi et al., 2011).
In the present study, we used the same number of BMSCtk
cells as that of tumor cells (BMSCtk/tumor cell ratio of 1:1).
The previous in vitro study testing the potency of the bystander
effect, using rat BMSCtk or HSVtk-transduced neural stem cells
and C6 cells at various ratios (BMSCtk/tumor cell ratio of 1:1 to
1:128) showed a very potent bystander effect up to BMSCtk/
tumor cell ratio of 1:16 (Amano et al., 2009; Li et al., 2005b).
Therefore, a dose response study at different BMSCtk/tumor
cell ratios should be also performed between different
BMSCtk/tumor cell combinations. In the present study, we
only performed a co-implantation study, because the aim of
the study was to test cell type- and species-specificity. We
obviously have to test the effect on an established intracranial
tumor as in our previous treatment studies (Amano et al., 2009;
Li et al., 2005a).
In vivo bystander effect between human BMSCtk and rat
glioma cells was a little weaker than that between human
BMSCtk and human glioma cells (Figs. 2 and 3), though the
difference was not very obvious in in vitro conditions (Fig. 1).
Precise mechanism is unknown but in vivo cell-to-cell commu-
nication, which is important for generation of bystander effect,
may be different between human and rat cells. Bystander
effect is still potent between cells of different species, but use
of human BMSCs is recommended for treatment of human
gliomas.
In conclusion, we have demonstrated that the bystander
effect by the human BMSCtk cells and GCV exerts against
various kinds of human brain tumor cells, and also against rat
glioma cells. Even after we changed the vector cells from
neural stem cells to BMSCs for convenience for clinical use, it is
still time-consuming to obtain sufficient number of BMSCtk
cells from the patients when considering the duration for
life-expectancy of glioblastoma patients. If pre-establishedallogeneic or heterogeneic vector cells can be used, the
strategy becomes much more feasible because those cells can
be used at the time of the initial operation of glioblastoma.
The results suggest that several established BMSCtk cell lines
prepared in advance can be used for the BMSC-based HSVtk/
GCV gene therapy of glioma patients provided that safety
issues due to immunological reactions are properly solved.
Then “BMSCtk therapy” would become easier and more
feasible as a treatment strategy for malignant gliomas that
is inevitably fatal at the present time.
Supplementary data to this article can be found online at
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